Product Details

Verart-L Suspension combines two complementary antimalarial agents for the effective treatment of uncomplicated malaria. Specifically, each 5ml delivers Artemether 20mg together with Lumefantrine 120mg. As a result, it offers fast-acting, combination antimalarial therapy in a convenient paediatric-friendly liquid formulation.

The suspension combines:

• Artemether (20mg per 5ml) – An artemisinin derivative that rapidly reduces parasite biomass by generating reactive oxygen species toxic to the malaria parasite. Consequently, it clears the majority of circulating parasites quickly, providing rapid symptomatic relief.
• Lumefantrine (120mg per 5ml) – A longer-acting antimalarial that clears the residual parasite population and reduces the risk of recrudescence. As a result, it complements Artemether’s rapid action with sustained antimalarial coverage, supporting complete parasite clearance.

Physicians prescribe Verart-L for the treatment of uncomplicated Plasmodium falciparum malaria and mixed malaria infections. In addition, its oral suspension format supports accurate weight-based paediatric dosing and easier administration than tablets, which is particularly valuable in young children affected by malaria. Because of this profile, Verart-L suits paediatric practices, general practice, and public health malaria treatment programs.

Key Features:

• Overall, this combination formulation guarantees pharmaceutical-grade purity across both actives
• Additionally, the dual-action formula combines rapid parasite clearance with sustained antimalarial coverage
• Furthermore, each 5ml delivers precise, validated dosage accuracy at 20mg + 120mg
• Notably, rigorous quality testing backs every stage of manufacturing
• Beyond that, light-protected bottle packaging preserves suspension stability
• Ultimately, a reliable supply chain suits bulk distribution to hospitals, clinics, and malaria treatment programs